Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Bicara Therapeutics (Nasdaq: BCAX) granted an inducement stock option to new Chief Commercial Officer Christopher Sarchi under its 2026 Inducement Plan, effective May 8, 2026.

The option covers 282,240 shares at an exercise price of $22.58, vesting over four-plus years under Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – BCAX

-6.21%

-6.21% Session close to close

In the May 13 session, BCAX declined 6.21%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.2% in the session following this news. A negative reaction despite this largely a...

Analysis

The stock moved -6.2% in the session following this news. A negative reaction despite this largely administrative inducement grant would contrast with the prior March 2026 inducement, which coincided with a positive move of 3.46%. The new award covers 282,240 shares at an exercise price of $22.58, tied to leadership hiring rather than capital raising. Recent insider sales and prior use of the $150,000,000 shelf could add to investor sensitivity, even when news centers on routine compensation structures.

Key Figures

Inducement option size: 282,240 shares Option exercise price: $22.58 per share Par value: $0.0001 per share +1 more

4 metrics

Inducement option size 282,240 shares Non-qualified stock option grant to new Chief Commercial Officer

Option exercise price $22.58 per share Equal to BCAX Nasdaq closing price on May 8, 2026

Par value $0.0001 per share Par value of Bicara common stock underlying option

Initial vesting portion 25% of shares Vests on first anniversary of start date, then quarterly thereafter

Historical Context

5 past events · Latest: May 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 11	Q1 2026 earnings	Positive	+1.5%	Reported Q1 2026 results, cash of $539.8M and ficerafusp alfa progress.
May 04	Earnings date set	Neutral	+4.8%	Scheduled Q1 2026 results and conference call for May 11, 2026.
Mar 30	FY 2025 earnings	Positive	+3.6%	Q4/FY 2025 results and Phase 3 FORTIFI-HN01 initiation and cash update.
Mar 23	Earnings date set	Neutral	-0.1%	Announced timing and logistics for FY 2025 results and business update.
Mar 04	Inducement option grant	Neutral	+3.5%	Granted non-qualified stock option for 115,000 shares under inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news events, including earnings and prior inducement grants, have generally seen share-price moves align directionally with the tone of the announcements.

Recent Company History

Over the last few months, BCAX has focused communications on financial updates and clinical progress for ficerafusp alfa. Q4 2025 and Q1 2026 earnings releases on Mar 30, 2026 and May 11, 2026 highlighted cash of $414.8M rising to $539.8M and funding into 1H 2029, with shares reacting positively. Earnings-date notices on Mar 23 and May 4 produced modest moves. A prior inducement option grant on Mar 4, 2026 also saw a positive reaction, framing today’s CCO inducement grant within a pattern of routine corporate and compensation disclosures.

Key Terms

inducement grant, non-qualified stock option, exercise price, Nasdaq Listing Rule 5635(c)(4)

4 terms

inducement grant financial

"it awarded an inducement grant to Christopher Sarchi under Bicara’s 2026 Inducement Plan"

An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.

non-qualified stock option financial

"Mr. Sarchi received a non-qualified stock option to purchase 282,240 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

exercise price financial

"with an exercise price of $22.58 per share, equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as a material inducement to the employee entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara’s 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara’s Chief Commercial Officer.

Mr. Sarchi received a non-qualified stock option to purchase 282,240 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $22.58 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on May 8, 2026. One-fourth of the shares vest on the first anniversary of Mr. Sarchi’s start date, with the remaining shares vesting in 12 equal quarterly installments thereafter, subject to his continued service with Bicara through each applicable vesting date.

Mr. Sarchi’s award was granted outside of Bicara’s stockholder-approved equity incentive plans and is pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026. The award was approved by the compensation committee of Bicara’s board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).

About Bicara Therapeutics
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors:
Rachel Frank
IR@bicara.com

Media:
Tim Palmer
tim.palmer@bicara.com 

FAQ

What inducement grant did Bicara Therapeutics (BCAX) award on May 8, 2026?

Bicara Therapeutics granted a non-qualified stock option for 282,240 common shares to Chief Commercial Officer Christopher Sarchi. According to Bicara, the option has a $22.58 exercise price and was issued under the 2026 Inducement Plan as a material inducement to his employment.

What are the vesting terms of Christopher Sarchi’s BCAX inducement stock option?

The BCAX inducement option vests over more than four years. According to Bicara, one-fourth vests on the first anniversary of Sarchi’s start date, and the remaining shares vest in 12 equal quarterly installments, subject to his continued service.

Why was the BCAX inducement grant made under Nasdaq Listing Rule 5635(c)(4)?

The grant was structured as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4). According to Bicara, the compensation committee of independent directors approved the award specifically to facilitate Sarchi entering into employment with the company.

Is the Bicara Therapeutics (BCAX) inducement stock option part of stockholder-approved equity plans?

The inducement stock option to Christopher Sarchi was granted outside Bicara’s stockholder-approved equity incentive plans. According to Bicara, it was issued under the separate 2026 Inducement Plan adopted by the board in January 2026 for hiring purposes.

What is the exercise price of the BCAX inducement option granted to Christopher Sarchi?

The exercise price of the BCAX inducement option is $22.58 per share. According to Bicara, this price equals the closing price of Bicara common stock on Nasdaq on May 8, 2026, aligning the award with then-current market value.